Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03278912
Recruitment Status : Recruiting
First Posted : September 12, 2017
Last Update Posted : November 8, 2019
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) )

Brief Summary:

Background:

PIDD stands for primary immune dysregulation. It is a general term that includes many different inherited immune system disorders. The immune system is the part of the body that helps fight disease and infection. People with PIDDs can develop many kinds of health problems. One of these is inflammatory bowel disease (IBD), which causes diarrhea and cramping. Researchers want to learn more about these disorders to develop possible treatments.

Objective:

To learn more about when and why IBD may develop in some people with PIDDs.

Eligibility:

People ages 3 and older who have PIDD or IBD.

Healthy volunteers in this age group are also needed.

Design:

Visit 1: Participants will be screened with physical exam, medical history, and blood and urine tests.

Visit 2: Participants will:

  • Have more physical exams and blood and urine tests.
  • Answer questions about quality of life and food history.
  • Provide a stool sample.
  • Have nasal and rectal skin swabs.
  • Have saliva collected.

Participants will have 1 follow-up visit per year. They will repeat visit 2 procedures.

Participants will be contacted by phone or email in between yearly visits. They will be asked about their health. They will complete a quality-of-life questionnaire and send a stool sample that is collected at home.

If participants experience a sudden change in symptoms or undergo a new treatment, they may be asked to complete visit 2 procedures.

If participants are not able to come to NIH, study data and samples can be collected without an in-person visit.

Participants will have a final study visit about 10 years after Visit 1. They will repeat visit 2 procedures.


Condition or disease
Chronic Granulomatous Disease Inflammatory Bowel Disease

Detailed Description:

Over 1 million people suffer from IBD in the United States. Although the exact pathogenesis is unclear, IBD results from an inappropriate inflammatory response to intestinal microbes which is influenced by the environment in a genetically susceptible host. IBDs can be classified as conventional (Crohn disease (CD) and ulcerative colitis (UC)) and unclassified (early onset, difficult to treat, associated with monogenic disorders and PIDDs). Among the 200 IBD susceptibility loci identified in genome-wide association studies (GWAS), overlap with aberrations identified in PIDDs has been observed, thereby supporting the study of PIDDs to better understand conventional IBD pathogenesis, while recognizing PIDD-associated IBDs as distinct disease entities requiring specialized management.

The prevalence of PIDDs worldwide is estimated at 1 in 2000 live births and encompasses a growing list of over 300 PIDDs. Despite the fact that GI disease is the second most common complication in patients with PIDDs (rates ranging from 5-50%), little is known about PIDDspecific

IBD pathogenesis and even less is understood about the role of the microbiota both as a consequence and modulator of immune response in these inherited disorders. Moreover, there may be a time-limited period ("immunological window of opportunity"), coinciding with the maturation of the host s microbiome, during which early immune education may have long-term effects on predisposition to aberrant immune responses and inflammatory dysregulation. The primary objective of this study is to determine if PIDDs result in intestinal dysbioses, which alter local and systemic immune responses. Our long-term goal is to comprehensively investigate the immunological window of opportunity as it relates to PIDD-associated IBDs to define time-sensitive immunoregulatory targets for therapeutic intervention. We will pursue this goal through a prospective, longitudinal study of pediatric and adult patients with PIDDs (with and without IBD) before and after treatment and/or diagnostic interventions, including but not limited to hematopoietic stem cell transplantation (HSCT). Findings from subjects with PIDDs will be compared to those from subjects with IBD as well as healthy volunteers. This multifaceted study will complement primary patient protocols while allowing for the direct interrogation of specific arms of innate and adaptive immunity in the context of host-microbiome interactions. Patients will be studied over time through the collection of clinical metadata, blood, stool, urine, saliva, skin swabs, and biopsies obtained from clinically-indicated endoscopies in age-appropriate patients. PIDDs of interest include but are not limited to: CGD, CTLA4 and LRBA protein deficiency, hypomorphic RAG deficiency, and IPEX syndrome.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 339 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Natural History of Intestinal Inflammation in Patients With Primary Immune Dysregulations
Estimated Study Start Date : November 13, 2019
Estimated Primary Completion Date : July 1, 2030
Estimated Study Completion Date : July 1, 2030


Group/Cohort
Healthy Volunteers
Healthy Volunteers
Patients with CGD without IBD
Patients with CGD without IBD
Patients with CGD-IBD
Patients with chronic granulomatous disease(CGD)-IBD
Patients with CTLA4 Defects
Patients with cytotoxic T-lymphocyte-associated protein 4 (CTLA4) defects
Patients with Hyper IgE Syndrome
Patients with Hyper IgE Syndrome
Patients with Hypomorphic RAG deficiency
Patients with hypomorphic recombination activating gene (RAG) deficiency
Patients with IBD only (no PIDD)
Patients with inflammatory bowel disease (IBD) (without a primary immune dysregulation (PIDD))
Patients with IPEX syndrome
Patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome
Patients with LAD-I
Patients with Leukocyte adhesion deficiency type I (LAD-I)
Patients with LRBA deficiency
Patients with lipopolysaccharide (LPS)-responsive-beige-likeanchor protein (LRBA) deficiency



Primary Outcome Measures :
  1. Disease specific intestinal microbiome signatures, and related localized and systemic immune responses. [ Time Frame: Baseline and Annual follow-up visits spanning 10 years ]
    Disease specific intestinal microbiome signatures, and related localized and systemic immune responses.


Secondary Outcome Measures :
  1. Changes in microbiome signatures. [ Time Frame: Baseline and Annual follow up visits spanning 10 years. ]
  2. Changes in systemic and tissue-specific markers of innate and adaptive immunity. [ Time Frame: Baseline and Annual follow up visits spanning 10 years ]
  3. Disease-specific differences in relative quantity and function of peripheral blood and tissue immune cells (includes hematopoietic and stromal cells). [ Time Frame: Throughout length of study ]
  4. Changes in metabolomic and transcriptomic signatures. [ Time Frame: Baseline and Annual follow-up visits spanning 10 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   3 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
The study population will include patients and healthy volunteers greater than or equal to 3 years of age; PIDDs of interest, IBD, and Non-PIDD/non-IBD (healthy volunteers)@@@@@@
Criteria
  • INCLUSION CRITERIA:
  • General Inclusion Criteria - All individuals must meet the following criteria to be eligible for study participation:

    • Age greater than or equal to 3 years.
    • Willing to allow storage of samples for future research.
    • Willing to allow genetic testing of their samples.
    • Negative urine or serum pregnancy test for women of childbearing potential.
  • Specific Inclusion Criteria for PIDD of Interest Cohort: Enrollment as a patient with confirmed PIDD or carrier status in a current NIH protocol, regardless of an IBD component.
  • Specific Inclusion Criteria for IBD Cohort:

    • Enrollment as a patient with confirmed IBD in a current NIH protocol.
    • Absence of clinical findings or history suggestive of a primary or acquired immunodeficiency (not including immunodeficiency caused by certain IBD treatments).
  • Specific Inclusion Criteria for non-PIDD/non-IBD Cohort (Healthy Volunteers):

    • Absence of clinical findings or history suggestive of a primary or acquired immunodeficiency.
    • Absence of clinical findings or history suggestive of IBD.

EXCLUSION CRITERIA:

  • General Exclusion Criteria - An individual who meets any of the following criteria will be excluded from study participation:

    • Active malignancy requiring treatment.
    • HIV.
    • Current treatment for hepatitis B.
    • Current treatment for hepatitis C.
    • Recreational IV drug use within the past 6 months (based on subject report).
    • Participation in a research study of an investigational vaccine within the past 6 months.
    • Any condition that, in the opinion of the investigator, contraindicates participation in this study.
  • Specific Exclusion Criteria for PIDD of Interest Cohort: None.
  • Specific Exclusion Criteria for IBD Cohort: None.
  • Specific Exclusion Criteria for non-PIDD/non-IBD Cohort (Healthy Volunteers):

    • Treatment with systemic antimicrobials within the past 3 months, unless it is a prophylactic regimen consisting of either an azole , trimethoprim-sulfamethoxazole, a quinolone, or any antimicrobial regimen resembling a typical prophylaxis regimen used to treat a PIDD of interest.
    • Treatment with immune modulators within the past 6 months.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03278912


Contacts
Layout table for location contacts
Contact: LaQuita N Snow, C.R.N.P. (240) 747-7717 laquita.snow@nih.gov

Locations
Layout table for location information
United States, Maryland
National Institutes of Health Clinical Center Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)    800-411-1222 ext TTY8664111010    prpl@cc.nih.gov   
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
Layout table for investigator information
Principal Investigator: Christa S Zerbe, M.D. National Institute of Allergy and Infectious Diseases (NIAID)

Additional Information:
Publications:
Layout table for additonal information
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT03278912     History of Changes
Other Study ID Numbers: 170163
17-I-0163
First Posted: September 12, 2017    Key Record Dates
Last Update Posted: November 8, 2019
Last Verified: June 25, 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) ):
Inflammatory Bowel Disease
Chronic Granulomatous Disease
Dysbiosis
Microbiome
Immunodeficiency
Additional relevant MeSH terms:
Layout table for MeSH terms
Intestinal Diseases
Inflammatory Bowel Diseases
Granulomatous Disease, Chronic
Inflammation
Pathologic Processes
Gastrointestinal Diseases
Digestive System Diseases
Gastroenteritis
Phagocyte Bactericidal Dysfunction
Leukocyte Disorders
Hematologic Diseases
Genetic Diseases, X-Linked
Genetic Diseases, Inborn
Immunologic Deficiency Syndromes
Immune System Diseases